Virus Destroying Or Inhibiting Patents (Class 514/3.7)
-
Publication number: 20120213802Abstract: The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR1 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR1 antagonists may be combined with a PAR2 agonist.Type: ApplicationFiled: November 15, 2010Publication date: August 23, 2012Inventors: Béatrice Riteau, Khaled Khoufache
-
Publication number: 20120202736Abstract: The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its functional equivalent for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition produced by the method of the present invention is effective in suppressing infections caused by viruses, bacteria, fungi, and parasites. Since the composition is developed in a form suitable for inhalation, it can directly provide the active ingredient to the sites of infection from these microbes, and thus treat and prevent respiratory infections and external wounds.Type: ApplicationFiled: April 18, 2012Publication date: August 9, 2012Applicant: DOBEEL CORPORATIONInventors: Hong Mo MOON, Jung Sun YUM, Byung Cheol AHN, Joo Youn LEE
-
Publication number: 20120201825Abstract: The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.Type: ApplicationFiled: April 19, 2011Publication date: August 9, 2012Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEURInventors: Frederic TANGY, Marianne Lucas-Hourani, Erika Navarro-Sanchez, Marie-Pascale Frenkiel, Hugues Bedouelle, Chantal Combredet, Philippe Despres
-
Patent number: 8236756Abstract: The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present invention furthermore provides a method of producing the prodrugs, to enhance brain and lymphatic delivery of drugs and/or to extend drug half-lives in plasma.Type: GrantFiled: May 10, 2004Date of Patent: August 7, 2012Assignees: Consejo Superior de Investigaciones Clentificas (CSIC), K.U. Leuven Research & DevelopmentInventors: Jan Balzarini, Maria José Camarasa Ríus, Sonsoles Velázquez Díaz
-
Publication number: 20120196793Abstract: A method to predict which patients will respond to a IAP inhibiting compound comprising administering an IAP inhibitor compound to a patient/and measuring IL1B, Lymphotoxin alpha (LTa), TWEAK, LIGHT, Fas, TNF alpha or TRAIL levels.Type: ApplicationFiled: September 17, 2010Publication date: August 2, 2012Inventors: Brant G. Firestone, Kymberly Levine, Dale A. Porter, John Sullivan, Leigh Zawel
-
Publication number: 20120196792Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.Type: ApplicationFiled: April 4, 2012Publication date: August 2, 2012Applicants: ENANTA PHARMACEUTICALS, INC., ABBOTT LABORATORIESInventors: Yiyin Ku, Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, Dale J. Kempf, David J. Grampovnik, Ying Sun, Dong Liu, Yonghua Gai, Yat Sun Or, Seble H. Wagaw, Ken Engstrom, Tim Grieme, Ahmad Sheikh, Jianzhang Mei
-
Patent number: 8232246Abstract: Compounds capable of inhibiting replication of the hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.Type: GrantFiled: June 30, 2009Date of Patent: July 31, 2012Assignee: Abbott LaboratoriesInventors: Keith F. McDaniel, Dale J. Kempf
-
Publication number: 20120189682Abstract: The present invention relates to a product comprising at least two antibiofilm agents wherein at least one of the antibiofilm agents is an antimicrobial peptide. The second antibiofilm agent is generally a dispersant or an anti-adhesive agent. There is also provided the use of the product in the treatment of a microbial infection.Type: ApplicationFiled: March 31, 2010Publication date: July 26, 2012Applicant: Novabiotics LimitedInventors: Deborah O'Neil, Derry Mercer, Cedric Charrier
-
Publication number: 20120184482Abstract: The invention relates to a ubiquitin-isopeptide probe (hereinafter also referred to as UIPP), a method for its preparation, and its use. The invention also provides a method for isolating a deubiquitinating enzyme and a method for activity-based protein profiling (ABPP).Type: ApplicationFiled: August 19, 2011Publication date: July 19, 2012Applicant: Helmholtz-Zentrum fuer Infektionsforschung GmbHInventors: Alexander Iphoefer, Raimo Franke, Antje Ritter, Tatjana Arnold, Lothar Jaensch
-
Patent number: 8222204Abstract: The present invention provides compositions useful for treating or preventing influenza infections. The composition comprises an isolated polypeptide including a sequence of at least 8 contiguous amino acid residues of the fusion initiation region (FIR) of an influenza hemagglutinin 2 protein or a peptide analog of the sequence. The FIR is a segment of the full length hemagglutinin 2 protein which is bounded by an amino-terminal region within the amino-terminal alpha-helix thereof and a carboxy terminus within the carboxy-terminal alpha-helix thereof, with a cysteine loop therebetween. The amino-terminal region of the FIR comprises a portion of the final 10 to 20 amino acid residues of the amino-terminal alpha-helix of the hemagglutinin 2 protein, and includes 3 or 4 hydrophobic amino acid residues, a positively-charged amino acid residue, a negatively-charged amino acid residue, and an aromatic amino acid residue.Type: GrantFiled: February 17, 2009Date of Patent: July 17, 2012Assignee: The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLCInventors: Robert F. Garry, Russell B. Wilson
-
Patent number: 8222203Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.Type: GrantFiled: December 12, 2008Date of Patent: July 17, 2012Assignee: Enanta Pharmaceuticals, Inc.Inventors: Ying Sun, Yonghua Gai, Yat Sun Or, Zhe Wang
-
Publication number: 20120178671Abstract: The inventors surprisingly found that specific oligosaccharides are capable of inhibiting viral replication through inhibiting NF-?B activation. The invention thus pertains to a composition comprising pectin (in the form of digalacturonic acid, trigalacturonic acid, polygalacturonic acid), Arabinoxylan from rice bran, ?-glucan from bakers yeast, D-Ribose or mixtures there-of for inhibiting viral replication in a mammal with a viral disease.Type: ApplicationFiled: June 21, 2010Publication date: July 12, 2012Inventors: Klaske Van Norren, Francina Jeannette Dijk, Benjamin Berkhout, Belinda Van't Land Potappel
-
Publication number: 20120177610Abstract: Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins. A complex of all proteins found currently in Plasma, Cryoprecipitate, Fraction III and many newly found proteins now being identified or any substances which are known proteins or unknown proteins which contain GOOD HEALTHY CELLS and the combination of any of these known or unknown proteins which contain any one of these GOOD HEALTHY cells: Neutrophil, Lymphocyte, Eosinophil, Basophil, and Marcophage, and their potential applications for treating a wide variety of diseases and other physical conditions and disorders, and for maintaining health.Type: ApplicationFiled: May 24, 2011Publication date: July 12, 2012Inventor: Kieu Hoang
-
Publication number: 20120171164Abstract: The present disclosure relates to the use of nutritional compositions including lactoferrin in supporting resistance to a viral respiratory tract infection. The method includes administering to a human a nutritional composition comprising a fat or lipid source, a protein source and lactoferrin produced by a non-human source.Type: ApplicationFiled: December 29, 2010Publication date: July 5, 2012Inventors: Anja Wittke, Dattatreya Banavara, Cecilia Munoz
-
Publication number: 20120172285Abstract: A series of stapled BCL-2 family peptide helices were identified as able to target the survival protein MCL-I with high affinity and a subset with unprecedented selectivity. Agents and methods for selective pharmacologic neutralization of MCL-I are provided for drug discovery and therapeutic uses, including use in overcoming the apoptotic resistance of cancer and other diseases associated with impaired cell death.Type: ApplicationFiled: December 9, 2009Publication date: July 5, 2012Inventors: Loren D. Walensky, Michelle L. Stewart
-
Patent number: 8211856Abstract: The present invention is directed to the use of the peptide compound Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.Type: GrantFiled: September 9, 2008Date of Patent: July 3, 2012Assignee: mondoBIOTECH Laboratories AGInventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
-
Publication number: 20120165249Abstract: Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus.Type: ApplicationFiled: February 2, 2012Publication date: June 28, 2012Inventors: Asim Kumar Debnath, Hongtao Zhang, Qian Zhao
-
Publication number: 20120164071Abstract: Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases.Type: ApplicationFiled: May 8, 2008Publication date: June 28, 2012Inventors: Philip E. Thorpe, M. Melina Soares, Jin He
-
Publication number: 20120164103Abstract: Compounds represented by formula I: or pharmaceutically acceptable salts and solvates thereof, wherein R1, X, Y, Y1, and Z are as defined herein, are useful for treating flaviviridae viral infections.Type: ApplicationFiled: March 9, 2012Publication date: June 28, 2012Applicant: Vertex Pharmaceuticals (Canada) IncorporatedInventors: Real Denis, Carl Poisson, Sanjoy Kumar Das, Irina Motorina, Rabindra Rej, Constantin G. Yannopoulos, Laval Chan Chun Kong
-
Publication number: 20120165248Abstract: Glutathione derivatives (GSH) of formula I are provided, wherein R is a thiol protection group. The derivatives are useful for the treatment of infections from Paramyxovirus, Orthomyxovirus, Herpes Simplex Virus and Acquired Immunodeficiency Syndrome Virus.Type: ApplicationFiled: October 12, 2011Publication date: June 28, 2012Applicant: fiRST S.r.l.Inventors: Umberto Benatti, Giorgio Brandi, Enrico Garaci, Mauro Magnani, Enrico Millo, Anna Taresa Palamara, Luigia Rossi
-
Publication number: 20120157371Abstract: The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPCs/HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.Type: ApplicationFiled: December 12, 2011Publication date: June 21, 2012Inventors: Chongxi YU, Lina Xu, Yuhua Chen, Binbing Yan, Shiqian Tu
-
Publication number: 20120142584Abstract: The present invention relates to novel transporter constructs of the generic formula (I) DlLLLxDm(LLLyDn)a and variants thereof. The present invention also refers to transporter cargo conjugate molecules, particularly of conjugates of the novel transporter constructs with a cargo moiety, e.g. proteins or peptides, nucleic acids, cytotoxic agents, organic molecules, etc. The present invention furthermore discloses (pharmaceutical) compositions comprising these conjugates and methods of treatment and uses involving such transporter constructs.Type: ApplicationFiled: December 22, 2009Publication date: June 7, 2012Applicant: XIGEN, S.A.Inventor: Christophe Bonny
-
Publication number: 20120141538Abstract: The present invention concerns modulators of the CX3CR1 receptor. More specifically, antagonists and agonists of the CX3CR1 receptor have been identified. These antagonists and agonists can be used for treating an inflammatory disorder, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a graft versus host disease, a behavioral disorder, a cicatrisation disorder, a viral infection, cancer or pain. They may also be used as an adjuvant in a vaccine composition.Type: ApplicationFiled: December 16, 2009Publication date: June 7, 2012Applicant: UNIVERSITE PIERRE ET MARIE CURIE -PARIS VIInventors: Guy Gorochov, Karim Dorgham, Christophe Combadiere, Philippe Deterre
-
Patent number: 8193149Abstract: The present invention is directed to the use of the peptide compound Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.Type: GrantFiled: September 9, 2008Date of Patent: June 5, 2012Assignee: mondoBIOTECH Laboratories AGInventors: Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher
-
Publication number: 20120129764Abstract: A synthesized or isolated influenza virus replication-inhibiting peptide that competitively inhibits protein-protein interaction of the PA and PB1 of both influenza Virus Types A and B and novel in vitro binding screen to identify peptides with antiviral activity against influenza viruses of both type A and B is disclosed. In addition to the well-known pandemic influenza A viruses (such as the 1918 “Spanish” flu or H5N1), both type A and B viruses contribute greatly to the annual recurring epidemics that cause the vast majority of human cases and medical cost. Surprisingly, it was found that the novel virus replication-inhibiting, are able to inhibit protein-protein interaction of the PA and PB1 subunits of the heterotrimeric viral RNA polymerase complex of both influenza virus types A and B.Type: ApplicationFiled: May 8, 2009Publication date: May 24, 2012Applicant: PIKE PHARMA GMBHInventors: Ulrich Kessler, Daniel Mayer, Kerstin Wunderlich, Charlene Rnadheera, Martin Schwemmle
-
Publication number: 20120121623Abstract: The present invention relates to monomeric and multimeric peptidic compounds which have antipathogenic, in particular antiviral or/and antibacterial activity. In a preferred aspect, the peptide compounds of the invention have an activity in respect of a broad spectrum of viruses, both DNA and RNA viruses, irrespective of whether they possess virus envelope or not. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, i.e. for the treatment or prevention of pathogenic, in particular viral or/and bacterial infections.Type: ApplicationFiled: August 5, 2010Publication date: May 17, 2012Applicant: SPIDERBIOTCH S.r.L.Inventors: Andrea Giuliani, Giovanna Pirri, Lorena Pizzuto, Santo Landolfo, Giorgio Gribaudo, David Lembo, Davide Gibellini
-
Patent number: 8178491Abstract: The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.Type: GrantFiled: June 26, 2008Date of Patent: May 15, 2012Assignee: Gilead Sciences, Inc.Inventors: Aesop Cho, Michael O'Neil Hanrahan Clarke, Choung U. Kim, John O. Link, Hyung-jung Pyun, Xiaoning C. Sheng, Qiaoyin Wu
-
Publication number: 20120114602Abstract: The present invention relates to a process for the synthesis of conjugates of glycosaminoglycanes (GAG) with biologically active molecules of varying nature, comprising small molecules and macro-molecules. In particular, the present invention relates to the conjugation of hyaluronic acid (HA) and its derivatives with polypeptides and proteins with a biological action, such as, for example, interferons, erythropoietins, growth factors, insulin, cytokines, antibodies and hormones. An object of the present invention also relates to isolatable intermediates obtained by the partial or total reaction of GAG with protected amino aldehydes in the conjugation process mentioned above.Type: ApplicationFiled: June 4, 2010Publication date: May 10, 2012Applicant: FIDIA FARMACEUTICI S.p.A.Inventors: Matteo D'Este, Davide Renier, Gianfranco Pasut, Antonio Rosato
-
Publication number: 20120114742Abstract: Methods are provided for the preparation of conjugates of a variety of bioactive components, especially proteins, with water-soluble polymers (e.g., poly(ethylene glycol) and derivatives thereof), which conjugates have reduced antigenicity and immunogenicity compared to similar conjugates prepared using poly(ethylene glycol) containing a methoxyl or another alkoxyl group. The invention also provides conjugates prepared by such methods, compositions comprising such conjugates, kits containing such conjugates or compositions and methods of use of the conjugates and compositions in diagnostic and therapeutic protocols.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: Mountain View Pharmaceuticals, Inc.Inventors: Alexa L. MARTINEZ, Merry R. Sherman, Mark G.P. Saifer, L. David Williams
-
Publication number: 20120114725Abstract: The present invention relates to an information medium to be handled by a large number of users, such as a banknote, and having antiviral properties, and to a method for making same.Type: ApplicationFiled: May 7, 2010Publication date: May 10, 2012Applicant: ARJOWIGGINS SECURITYInventor: Henri Rosset
-
Publication number: 20120114596Abstract: It relates to the treatment or prevention of a chronic viral infection with a Thymic Stromal Lymphopoietin (TSLP) antagonist thereby avoiding immune evasion and persistence of the virus. It also provides a method of prognosing the evolution of a cervical dysplasia by TSLP expression in a sample of said cervical dysplasia.Type: ApplicationFiled: February 1, 2010Publication date: May 10, 2012Applicants: INSTITUT CURIE, Heinrich-Heine-Universitaet, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM)Inventors: Vassili Soumelis, Isabel Fernandez, Bernhard Homey
-
Publication number: 20120114679Abstract: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in humans, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier.Type: ApplicationFiled: November 28, 2011Publication date: May 10, 2012Applicant: Nymox Pharmaceutical CorporationInventors: Paul Averback, Jack Gemmell
-
Patent number: 8173131Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.Type: GrantFiled: May 26, 2005Date of Patent: May 8, 2012Assignee: PerkinElmer Health Sciences, Inc.Inventors: Ralph A. Tripp, Les Jones, Larry J. Anderson
-
Publication number: 20120107319Abstract: The invention relates to pharmaceutical and vaccine compositions comprising an antibody binding specifically to the intracellular domain of EBV protein LMP1.Type: ApplicationFiled: August 7, 2009Publication date: May 3, 2012Applicants: Centre National De La Recherche Scientifique(CNRS), UNIVERSITE CLAUDE BERNAND LYON 1Inventor: Tadamasa Ooka
-
Patent number: 8168193Abstract: A method for controlling a flavivirus entry into a cell, kits for assaying the flavivirus entry into the cell, and methods of treating and preventing flaviviruses infections are disclosed, together with vaccine and pharmaceutical compositions.Type: GrantFiled: January 26, 2011Date of Patent: May 1, 2012Assignee: National University of SingaporeInventors: Mary Mah Lee Ng, Justin Jan Hann Chu
-
Patent number: 8168748Abstract: Polypeptides and fusion proteins that bind to eukaryotic viruses, in particular, eukaryotic single-stranded DNA (ssDNA) viruses are provided. The polypeptides and fusion proteins bind to the replication initiation proteins (Rep) of ssDNA viruses and optionally inhibit viral replication and/or viral infection. The virus can be a plant pathogen or animal pathogen. Consensus sequences used to identify polypeptides that bind to eukaryotic viruses are also provided.Type: GrantFiled: August 4, 2006Date of Patent: May 1, 2012Assignee: North Carolina State UniversityInventors: Linda Hanley-Bowdoin, Luisa Lopez-Ochoa
-
Patent number: 8168750Abstract: A nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, a DNA construct including a replicable expression vector and at least one heterologous nucleic acid, and recombinant protein including fragment of the adenovirus fiber capsid protein. The fragment comprises the C-terminal knob and part of the shaft domain of the fiber protein of these adenoviruses. The use of recombinant proteins as an active ingredient in vaccinating compositions for conferring to an animal immunity against a pathogenic infection by an adenovirus, and methods for vaccinating a domestic bird against a pathogenic adenoviral infection.Type: GrantFiled: December 6, 2010Date of Patent: May 1, 2012Assignee: ABIC Biological Laboratories Ltd.Inventors: Jacob Pitcovski, Elena Fingerut, Bezalel Gutter, Gilad Gallili, Amnon Michael
-
Publication number: 20120101031Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.Type: ApplicationFiled: June 7, 2011Publication date: April 26, 2012Applicants: ENANTA PHARMACEUTICALS, INC., ABBOTT LABORATORIESInventors: Hui-Ju Chen, Keith F. McDaniel, Brian E. Green, Jason P. Shanley, Albert W. Kruger, Jorge Gandarilla, Dennie S. Welch, Russell D. Cink, Steven C. Cullen, Yonghua Gai, Guoqiang Wang, Yat Sun Or
-
Publication number: 20120101028Abstract: The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-?B-dependent target gene expression in a cell.Type: ApplicationFiled: August 8, 2011Publication date: April 26, 2012Applicant: Yale UniversityInventors: Michael J. May, Sankar Ghosh
-
Publication number: 20120101025Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: ApplicationFiled: December 30, 2011Publication date: April 26, 2012Applicant: ONYX THERAPEUTICS, INC.Inventors: Mark S. Smyth, Guy J. Laidig, Ronald T. Borchardt, Barry A. Bunin, Craig M. Crews, John H. Musser, Kevin D. Shenk, Peggy A. Radel
-
Publication number: 20120101026Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: ApplicationFiled: December 30, 2011Publication date: April 26, 2012Applicant: ONYX THERAPEUTICS, INC.Inventors: Mark S. Smyth, Guy J. Laidig, Ronald T. Borchardt, Barry A. Bunin, Craig M. Crews, John H. Musser, Kevin D. Shenk, Peggy A. Radel
-
Publication number: 20120100186Abstract: Nanoparticulate compositions which employ membrane-integrating peptides to effect contraception and/or protection against infection by sexually transmitted virus are described.Type: ApplicationFiled: October 20, 2011Publication date: April 26, 2012Applicant: Washington UniversityInventors: Samuel A. WICKLINE, Gregory LANZA, Joshua HOOD
-
Patent number: 8163693Abstract: The invention provides compounds urea-containing peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables T, R1-R9, J, L, M, Y, Z, m, n, and t are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain urea-containing peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more urea containing peptides compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such pharmaceutical compositions may contain a urea containing peptides compound as the only active agent or may contain a combination of a urea containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.Type: GrantFiled: September 24, 2008Date of Patent: April 24, 2012Assignee: Achillion Pharmaceuticals, Inc.Inventors: Dawei Chen, Milind Deshpande, Avinash Phadke
-
Publication number: 20120093776Abstract: Described herein are methods, uses, and pharmaceutical compositions for treating heart disease that include a bone morphogenetic protein (BMP). In addition, described herein are methods, uses, and compositions for preventing or slowing fibrosis in diseased or injured tissue, and/or for preventing or slowing cell death in diseased or injured tissue.Type: ApplicationFiled: March 30, 2010Publication date: April 19, 2012Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATIONInventors: Weinian Shou, Hanying Chen, Loren J. Field
-
Publication number: 20120093738Abstract: The present invention relates to taste-masked oral formulations of influenza antivirals. The taste-masked pharmaceutical formulations for oral administration comprise one or more influenza antivirals, at least one taste-masking agent and at least one pharmaceutically acceptable excipient. Further, the taste-masked influenza antiviral formulations of the present invention are provided in the form of dispersible tablets, effervescent tablets, orally disintegrating tablets, chewable tablets, bite-dispersion tablets or the like, wherein the bitter taste of influenza antivirals is masked thereby providing palatable formulations.Type: ApplicationFiled: June 10, 2010Publication date: April 19, 2012Applicant: Rubicon Research Private LimitedInventors: Pratibha Sudhir Pilgaonkar, Maharukh Tehmasp Rustomjee, Anilkumar Surendrakumar Gandhi
-
Publication number: 20120090043Abstract: The invention concerns an isolated complex comprising an HIV or HTLV protein and a human protein. Corresponding nucleic acids, vectors, host cells, host organisms, compositions, kits, medical uses, diagnostic uses, and methods of screening agents are also contemplated. Disclosed are 212 interactions between 19 retroviral proteins and 131 human proteins.Type: ApplicationFiled: June 30, 2010Publication date: April 12, 2012Applicant: UNIVERSITE DE LIEGEInventors: Jean-Claude Twizere, Nicolas Simonis
-
Patent number: 8143213Abstract: A method of inhibiting a retrovirus production, the method includes administering a retrovirus inhibitor selected from at least one of a TULA protein, a fragment of TULA containing a UBA domain, a UBA domain of TULA, a peptide mimicking TULA, a peptide mimicking a fragment of TULA containing a UBA domain, a peptide mimicking a UBA domain of TULA, a polynucleotide encoding TULA, a polynucleotide encoding a fragment of TULA containing a UBA domain, a polynucleotide encoding a UBA domain of TULA, a polynucleotide encoding a peptide mimicking TULA, a polynucleotide encoding a peptide mimicking a fragment of TULA containing a UBA domain, a polynucleotide encoding a peptide mimicking the UBA domain of TULA, fragments thereof, muteins thereof, variants and splice variants thereof, and combinations thereof to a cell or a tissue infected by a retrovirus.Type: GrantFiled: September 17, 2007Date of Patent: March 27, 2012Assignee: Temple University—of The Commonwealth System of Higher EducationInventors: Alexander Tsygankov, Evgeniya Smirnova
-
Publication number: 20120070489Abstract: The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor.Type: ApplicationFiled: September 14, 2011Publication date: March 22, 2012Inventors: BEN M. DUNN, JANET K. YAMAMOTO, MAKI ARAI
-
Publication number: 20120071397Abstract: The present invention provides methods for treating a subject undergoing hematopoietic stem cell transplantation, methods for increasing a subject's resistance to bacterial or viral infection during and/or following hematopoietic stem cell transplantation, and methods for treating norovirus infection.Type: ApplicationFiled: August 10, 2011Publication date: March 22, 2012Applicant: University of Southern CaliforniaInventors: Kathleen E. Rodgers, Gere S. diZerega
-
Patent number: RE43298Abstract: The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.Type: GrantFiled: April 22, 2011Date of Patent: April 3, 2012Assignees: Schering Corporation, Dendreon CorporationInventors: Anil K. Saksena, Viyyoor Moopil Girijavallabhan, Raymond G. Lovey, Edwin Jao, Frank Bennett, Jinping L. McCormick, Haiyan Wang, Russell E. Pike, Stephane L. Bogen, Tin-Yau Chan, Yi-Tsung Liu, Zhaoning Zhu, F. George Njoroge, Ashok Arasappan, Tejal Parekh, Ashit K. Ganguly, Kevin X. Chen, Srikanth Venkatraman, Henry M. Vaccaro, Patrick A. Pinto, Bama Santhanam, Scott Jeffrey Kemp, Odile Esther Levy, Marguerita Lim-Wilby, Susan Y. Tamura, Wanli Wu, Siska Hendrata, Yuhua Huang